Literature DB >> 18779929

Focal liver lesions in cirrhosis: value of contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels.

M D'Onofrio1, N Faccioli, G Zamboni, R Malagò, S Caffarri, G Fattovich, R Pozzi Mucelli.   

Abstract

PURPOSE: This study aimed to evaluate the diagnostic value of contrast-enhanced ultrasound (CEUS) in characterising focal liver lesions in cirrhosis and to validate its use in lesions discovered during surveillance for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Between 2003 and 2006, 128 cirrhotic patients with focal liver lesions at baseline ultrasonography (US) were studied by power colour Doppler US (Doppler US) and CEUS. Serum alpha-fetoprotein (AFP) levels were assessed in all patients. Fine-needle biopsy or other reference modalities such as computed tomography (CT), magnetic resonance imaging (MRI) or digital subtraction angiography (DSA) were used as the gold standard. The accuracy of baseline US, Doppler US, AFP levels, combined US and AFP levels and combined US, Doppler US and CEUS in characterising focal liver lesions was assessed. Diagnostic performance was compared using the McNemar test.
RESULTS: A total of 207 focal liver lesions (101 benign and 106 malignant) were identified in 128 patients. CEUS sensitivity and specificity for lesion characterisation were 96.2% and 97.0%, respectively, whereas its positive and negative predictive values were 97.1% and 96.1%. CEUS accuracy was 96.6%, higher than that of US (72.0%), Doppler US (70.0%), AFP levels (65.7%), combined US and Doppler US (70.0%) and combined US and AFP levels (90.3%). The differences between US and CEUS were statistically significant (p<0.05).
CONCLUSIONS: CEUS can characterise focal liver lesions with 96.6% accuracy, a value higher than US, Doppler US, AFP levels, combined US and AFP levels and combined US and Doppler US. CEUS should therefore be used to characterise focal liver lesions detected during HCC surveillance of cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779929     DOI: 10.1007/s11547-008-0316-z

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  32 in total

Review 1.  The role of contrast-enhanced ultrasound in the characterisation of focal liver lesions.

Authors:  E Leen
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

2.  Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.

Authors:  Emilio Quaia; Fabrizio Calliada; Michele Bertolotto; Sandro Rossi; Lorena Garioni; Laura Rosa; Roberto Pozzi-Mucelli
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

3.  Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.

Authors:  Carlos Nicolau; Violeta Catalá; Ramón Vilana; Rosa Gilabert; Luis Bianchi; Manel Solé; Mario Pagés; Concepció Brú
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

4.  Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrast-enhanced ultrasound.

Authors:  Tommaso Vincenzo Bartolotta; Adele Taibbi; Massimo Galia; Giuseppe Runza; Domenica Matranga; Massimo Midiri; Roberto Lagalla
Journal:  Eur Radiol       Date:  2006-10-03       Impact factor: 5.315

Review 5.  A revolution in liver ultrasound.

Authors:  David Owen Cosgrove
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-01       Impact factor: 2.566

Review 6.  Hepatic imaging in the 21st century.

Authors:  Emil I Cohen; Eric J Wilck; Robert S Shapiro
Journal:  Semin Liver Dis       Date:  2006-11       Impact factor: 6.115

Review 7.  From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls.

Authors:  R L Baron; M S Peterson
Journal:  Radiographics       Date:  2001-10       Impact factor: 5.333

8.  Screening for hepatocellular carcinoma.

Authors:  S De Masi; M E Tosti; A Mele
Journal:  Dig Liver Dis       Date:  2005-01-26       Impact factor: 4.088

Review 9.  Ultrasound of focal liver lesions.

Authors:  C J Harvey; T Albrecht
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

10.  The use of contrast-enhanced ultrasound in the management of the cirrhotic patient and for detection of HCC.

Authors:  C Nicolau; R Vilana; C Brú
Journal:  Eur Radiol       Date:  2004-10       Impact factor: 5.315

View more
  10 in total

1.  Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent.

Authors:  T V Bartolotta; A Taibbi; M Midiri; L La Grutta; M De Maria; R Lagalla
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

Review 2.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

3.  Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma.

Authors:  A Gallotti; M D'Onofrio; A Ruzzenente; E Martone; R De Robertis; A Guglielmi; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2009-09-05       Impact factor: 3.469

4.  Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging.

Authors:  Michele Di Martino; Gianmaria De Filippis; Adriano De Santis; Daniel Geiger; Maurizio Del Monte; Concetta Valentina Lombardo; Massimo Rossi; Stefano Ginanni Corradini; Gianluca Mennini; Carlo Catalano
Journal:  Eur Radiol       Date:  2012-11-18       Impact factor: 5.315

5.  [Hepatocellular carcinoma in rural Burkina Faso Africa: contribution of ultrasound, about 58 cases].

Authors:  Zakari Nikièma; Appolinaire Sawadogo; Carole Gilberte Kyelem; Rabiou Cissé
Journal:  Pan Afr Med J       Date:  2010-11-04

6.  Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.

Authors:  M Sadeghi; I Lahdou; H Oweira; V Daniel; P Terness; J Schmidt; K-H Weiss; T Longerich; P Schemmer; G Opelz; A Mehrabi
Journal:  Br J Cancer       Date:  2015-08-13       Impact factor: 7.640

7.  Comparison of the Accuracy of DWI and Ultrasonography in Screening Hepatocellular Carcinoma in Patients With Chronic Liver Disease.

Authors:  Reza Jalli; Seyed Hamed Jafari; Sepideh Sefidbakht; Kourosh Kazemi
Journal:  Iran J Radiol       Date:  2015-01-01       Impact factor: 0.212

8.  Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis.

Authors:  Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer
Journal:  Hepatol Commun       Date:  2022-08-09

9.  Clinical and contrast-enhanced image features in the prediction model for the detection of small hepatocellular carcinomas.

Authors:  Ming-Feng Chiang; Tse-Kai Tseng; Chia-Wen Shih; Tzeng-Huey Yang; Szu-Yuan Wu
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

10.  Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Johannes Chang; Alexia Dumitrache; Nina Böhling; Jasmin Abu-Omar; Carsten Meyer; Deike Strobel; Julian Luetkens; Andreas Minh Luu; Jürgen Rockstroh; Christian P Strassburg; Jonel Trebicka; Maria A Gonzalez-Carmona; Milka Marinova; Michael Praktiknjo
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.